

Recommendations closed due to risks being accepted, being no longer applicable or being withdrawn, or due to disagreements with audit recommendations

In 2022, three recommendations were closed due to being no longer applicable:

Report reference / title/issue date	Observation title, recommendation (reference and priority)	IAIG assessment
IAIG/11008 Internal audit report of PharmaMX project for acquisition of medicines in Mexico ID 22731-001 28 December 2021	<p><u>Finalization of procurement approaches and other strategies, IAIG/11008/06 (Medium)</u></p> <p>Follow up on the completion of the technical note with proposed methodology for establishing reasonableness of cost analysis for pharmaceuticals, to be considered for Phase II procurement as a pilot; coordinate procurement team activities with the country office Risk Management Team to deploy the agreed due diligence approach by Q2 of 2022; ensure that suggestions received from the Procurement Group, if any, and changes to Section I of the solicitation documents have been incorporated in the ITBs for Phase II, in both the Spanish and English versions, prior to their publication and during the tender process as amendments, as well as the incorporation of the procurement strategy; revise the negotiation strategy used for ITBs in Phase I and consider lessons learned and suggestions for improvement for Phase II negotiations, and ensure that any deviation is timely discussed with the Procurement Group; and share the recently finalized Project's exit strategy with UNOPS Legal Group for review; ensure that the analysis comparing the variation of COVID-19 medicine prices in the region developed by the Regional Observatory of Prices is considered during Phase II, as a source of information and analysis, as applicable; ensure the creation of a specialized market research area within the project as included in the business case presented, who will also perform background check activities for the bidding process of 2022. Continue the analysis of the GOB360 platform and analyse the results of the healing material market research already requested; the savings calculation methodology for the project Phase II will be based on the Maximum Reference Price indicated by Mexico's Institute of Health for Welfare (INSABI) in the latest communication received; the Communications Strategy for the year 2022 will be executed upon approval of UNOPS Global Head of Communications; and the business case developed to assess feasibility of using incoterms other than Delivered Duty Paid in future procurement will be reviewed and discussed with the Regional Advisors, the Procurement Group and project procurement team.</p>	Recommendation no longer applicable due to the termination of the PharmaMX project.
	<p><u>Reasonableness of cost and value for money, IAIG/11008/11 (High)</u></p> <p>Ensure that the Technical Note for establishing reasonableness of cost analysis for pharmaceuticals is aligned with project objectives; and monitor all procurement activities and implementation of procurement strategies along with the PM in weekly procurement checkpoints and with the team responsible for procurement outcomes.</p>	
	<p><u>Forecasting and quantification, IAIG/11008/16 (Medium)</u></p> <p>Propose a meeting with INSABI to discuss the approach to address the CNIS (Compendio Nacional de Insumos para la Salud); share with INSABI the information related to keys without sanitary registration or low competence in Mexico that UNOPS detects in the process; request from INSABI information on consumption by pathology, by entity and/or federal state, as well as inventories held by institutions or CLUES (Clave Unica de Establecimientos de Salud) and logistics operators; and activate the use of available LTAs signed during Phase I as a way to minimize the impact of the frequent changes on quantities required.</p>	